Semaglutide GLP-1 is formulated to provide long-lasting appetite control because it is typically administered once per week
3 The potential CV and renal effects of linagliptin have been investigated in the CAROLINA and CARMELINA trials
References Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al
Regular follow-up appointments, typically scheduled every 4 to 12 weeks during the initial treatment phase, allow for dose adjustments, side effect management, and monitoring of therapeutic outcomes
Tesamorelin is FDA-indicated for reducing excess abdominal fat in HIV-associated lipodystrophy, and the label states it is not indicated for weight loss management